Investor syndicate includes leading biotech and mutual funds. HOUSTON–BUSINESS WIRE–Bellicum Pharmaceuticals, Inc., a biotechnology company focused on developing safer and more effective cellular immunotherapies, today announced the successful completion of a $55M Series C financing. The funding will be used to expand the clinical evaluation of Bellicum’s stem cell transplant, chimeric antigen receptor (CAR) T …
Avoro News
Contact Us
110 Greene Street, Suite 800
New York, NY 10012
+1 212.937.4970
info@avorocapital.com